secwatch / observer
8-K filed July 6, 2023, 7:59 PM ET ticker MYGN CIK 0000899923
debt confidence high sentiment positive materiality 0.55

MYRIAD GENETICS INC (MYGN): debt financing — Myriad Genetics establishes new $90M asset-based credit facility expandable to $115M

MYRIAD GENETICS INC

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

MYRIAD GENETICS INC incurred revolving credit of $90,000,000 with JP Morgan Chase Bank, N.A., as Administrative Agent and as Issuing Bank at ABR plus an applicable margin ranging from 1.00% to 1.50% or Adjusted Term SOFR maturing June 30, 2026.

Instrument
revolving credit
Principal
$90,000,000
Counterparty
JP Morgan Chase Bank, N.A., as Administrative Agent and as Issuing Bank
Rate
ABR plus an applicable margin ranging from 1.00% to 1.50% or Adjusted Term SOFR
Maturity
June 30, 2026
Event
incurrence
Exact text from the filing
On June 30, 2023 (the "Closing Date"), Myriad Genetics, Inc. (the "Company") entered into a Credit Agreement (the "Credit Agreement") with the lenders from time to time party thereto ("Lenders"), certain of the Company's domestic subsidiaries party thereto (the "Guarantors"), and JP Morgan Chase Bank, N.A., as Administrative Agent (in such capacity, "Administrative Agent") and as Issuing Bank, consisting of a revolving credit facility in an initial maximum principal amount of $90,000,000, with an option to increase the maximum principal amount by up to $25,000,000 (the "Credit Facility").
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MYRIAD GENETICS INC entered into Credit Agreement with JP Morgan Chase Bank, N.A., as Administrative Agent and as Issuing Bank, and the lenders from time to time party thereto valued at $90,000,000 (effective 2023-06-30).

Action
entry
Agreement
credit facility
Counterparty
JP Morgan Chase Bank, N.A., as Administrative Agent and as Issuing Bank, and the lenders from time to time party thereto
Value
$90,000,000
Effective
2023-06-30
Exact text from the filing
On June 30, 2023 (the “Closing Date”), Myriad Genetics, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with the lenders from time to time party thereto (“Lenders”), certain of the Company’s domestic subsidiaries party thereto (the “Guarantors”), and JP Morgan Chase Bank, N.A., as Administrative Agent (in such capacity, “Administrative Agent”) and as Issuing Bank, consisting of a revolving credit facility in an initial maximum principal amount of $90,000,000, with an option to increase the maximum principal amount by up to $25,000,000 (the “Credit Facility”).
View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

MYRIAD GENETICS INC filing history →

Source: SEC EDGAR
accession 0000899923-23-000047
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.